Quick Facts on Citafort

• Approved Use: Management of major depressive disorder (MDD) in adults.
• Other Uses: May be used to address generalized anxiety disorder (GAD) in adults.
• Therapeutic Aim: Supports the reduction of symptoms associated with these conditions.

---

Citafort is a prescription medication utilized in therapeutic settings for the management of mental health conditions. Its primary approved use is to address the symptoms of major depressive disorder in adult patients. Administration is intended to help reduce feelings of low mood, loss of interest, and other characteristic manifestations of this condition.

In addition to its primary approved use, healthcare providers may utilize Citafort to support the management of generalized anxiety disorder in adults, with the aim of helping to lessen excessive worry and tension. The role of the medication is to support patients in their overall treatment plan for these domains.

Regulatory References

1. NIH MedlinePlus guidance on SSRI class medications

Who Can and Cannot Use Citafort?

Citafort's eligibility is strictly defined by regulatory documents, focusing on patient age, concurrent medications, and pre-existing health conditions. The official guidelines establish clear constraints for use.

Absolute Contraindications

Citafort is contraindicated and must not be used by individuals with a known hypersensitivity to escitalopram or citalopram. Use is also strictly prohibited for patients concurrently taking Monoamine Oxidase Inhibitors (MAOIs), including linezolid and intravenous methylene blue, or the medicine Pimozide. Additionally, the medicine is contraindicated in patients with known QT interval prolongation or those taking any other QT-prolonging medicines.

---

Age and Restricted Use

The medication is approved for use in adults and adolescents 12 years and older for Major Depressive Disorder (MDD); however, safety and effectiveness are not established for children under 12 years of age. Older adults require a restricted maximum daily dose as defined by regulatory bodies. Use requires caution and a specific maximum dose in patients with hepatic impairment. Caution is also warranted for those with severe renal impairment or a history of seizure or mania. During pregnancy and lactation, use is permitted only after a regulatory risk-benefit assessment.

Interactions with other medicines and products

Contraindicated Combinations

Co-administration of Citafort (Escitalopram) is formally prohibited with specific medicinal products as documented by regulatory authorities. The use of Citafort is contraindicated with Monoamine Oxidase Inhibitors (MAOIs), including Linezolid and intravenous Methylene Blue, due to the established risk of Serotonin Syndrome. Furthermore, co-administration with Pimozide and other medicinal products known to prolong the QT interval is also contraindicated.

Pharmacokinetic and Pharmacodynamic Interactions

The metabolism of Escitalopram primarily involves the CYP2C19 and CYP3A4 liver enzymes. Co-administration with strong inhibitors of these enzymes, such as Cimetidine, is officially documented to increase the overall plasma concentration (exposure) of Escitalopram. Conversely, Escitalopram acts as a modest inhibitor of CYP2D6, which may increase the exposure of co-administered drugs that are substrates for this enzyme, such as Metoprolol.

Pharmacodynamically, co-administration with other serotonergic agents (e.g., Triptans, Tramadol, Lithium) increases the potential for Serotonin Syndrome. Combining Citafort with drugs that interfere with hemostasis, including NSAIDs and Warfarin, is documented to increase the risk of abnormal bleeding. For timing restrictions, a 14-day washout period is mandatory when switching between MAOIs and Citafort. The use of the herbal product St. John's Wort is also restricted due to increased serotonergic risk, and the regulatory label advises the avoidance of alcohol.

Inhibiting Serotonin Reuptake

Citafort primarily acts as a selective inhibitor of the Serotonin Transporter (SERT), a protein that facilitates the rapid removal of the neurotransmitter serotonin from the synaptic cleft. By blocking SERT, the drug prevents this reuptake mechanism, causing an immediate and sustained elevation of serotonin concentration in the space between nerve cells.

Modulating Central Serotonergic Signaling

The increase in synaptic serotonin enhances and stabilizes communication within the central serotonergic system and associated neural circuits. This sustained modulation leads to adaptive changes in receptor sensitivity and activity over time, which results in altered patterns of receptor activation and signal transduction across the pathways.

Persistent Shift in Neural Activity

The long-term consequence of enhanced and stabilized serotonergic signaling is a persistent, elevated postsynaptic signaling state that shifts the baseline activity of affected neural circuits in specific, high-level processing centers within the brain. This action influences the downstream firing rate and synaptic connectivity, resulting in a persistent change in the signal flow through affected neuronal systems.

Official Administration Guidelines for Citafort (Escitalopram)

Citafort is a medication designated for oral administration, available as film-coated tablets (typically 5 mg, 10 mg, and 20 mg strengths) and an oral solution. The medication is taken once daily, and the intake is flexible, as it may be administered with or without food.

Standard Usage and Dosage Patterns

The standard starting dosage for adults with Major Depressive Disorder or Generalized Anxiety Disorder is 10 mg once daily. Based on clinical assessment, the dosage may be increased up to a maximum recommended dose of 20 mg once daily. Any dose adjustment, such as moving from 10 mg to 20 mg, is officially recommended to occur no sooner than one week after the previous change to allow for a steady state to be reached.

The 10 mg and 20 mg tablets are typically scored, a feature that facilitates dose management and allows for the administration of a 5 mg dose by division. While the timing is flexible (morning or evening), the frequency remains strictly once every 24 hours. If a dose is missed, the official advice is to skip the forgotten dose and resume the schedule at the next regularly scheduled time; taking two doses at once is not recommended.

Population-Specific Constraints

Regulatory guidance defines specific maximum dosage constraints for certain patient groups. For older adults (aged 65 years and over) and patients diagnosed with hepatic impairment, the maximum recommended daily dose is constrained to 10 mg. The overall treatment course is typically long-term, and discontinuation must be procedural, involving a gradual dose reduction (tapering) over a period of time to minimize procedural constraints.

Citafort: Recent Clinical Evidence

Evidence for Major Depressive Disorder (MDD)

Research has explored Citafort for use in conditions characterized by major depressive disorder (MDD), focusing primarily on adults. Data is derived from randomized controlled trials (RCTs), systematic reviews, and meta-analyses that monitored patient groups and tracked symptom evolution over defined time intervals. Studies monitored outcomes related to symptom change when Citafort was compared to an inactive treatment (placebo) or was observed in comparison to other licensed treatments. Findings contribute to the broader evidence landscape, particularly regarding changes measured during the short-term study period. The evidence landscape includes some limitations. Long-term effects are not fully established across all patient groups, and existing studies provide limited insight into what patterns the research observed in certain complex subgroups within the general adult population.

Evidence for Generalized Anxiety Disorder (GAD)

For Generalized Anxiety Disorder (GAD), Citafort was studied for its use in conditions characterized by fluctuating or episodic manifestations of anxiety. The research base includes double-blind, placebo-controlled randomized trials that examined patient-reported experiences of worry and tension. These studies explored short-term symptom changes, monitoring outcomes related to physical discomfort and daily functioning. Research examined outcomes related to symptom evolution during the study, including the documentation of defined response and remission criteria. Data are still emerging regarding the relevance of individual genetic profiles (pharmacogenetics) in relation to observed responses.

Long-Term Studies and Follow-Up

The research landscape includes dedicated studies observing responses over defined time intervals to understand the duration of Citafort use. For both MDD and GAD, follow-up durations were monitored to assess patterns related to the return of symptoms. For adult patients with MDD, studies tracked these patterns for those who continued the medicine after achieving initial stability. Research provides insight into short-term changes; however, long-term effects are not fully established for all aspects of the conditions studied.

Evidence in Specific Patient Populations

Research examined Citafort in populations beyond the general adult group. Specifically, research has explored Citafort for use in adolescents (ages 12 to 18) with MDD and was evaluated in pediatric subjects (ages 7 to 17) with GAD. Studies examined symptom change using age-appropriate scales. Research documents patterns in these younger groups. Results apply only to the populations studied. Data for certain other groups, such as older adults with complex health issues, remain insufficient.

What Research Still Seeks to Understand

Certainty remains low in some research areas. While the evidence highlights what is known, there are still areas where research is ongoing or where data are limited. For example, the precise reasons for the varied outcomes observed in the study populations are a subject of continuous research, including the exploration of individual biological markers. Long-term effects related to this medicine are not fully established in all special populations, and findings were mixed in some initial studies in the youngest populations.

Common questions about Citafort (FAQ)

Q: How quickly should someone notice the effects of Citafort?

Studies used to authorize the drug's use measured its effectiveness over periods up to eight weeks. While some people may notice changes sooner, official information indicates that the full scope of the therapeutic effect is typically assessed after several weeks of continuous treatment.

---

Q: Does Citafort have an immediate or a gradual effect?

According to official prescribing information, the medication's effect is gradual rather than immediate. This is because the chemical changes in the brain that influence mood and anxiety take time to fully develop and stabilize. Official documents indicate the concentration usually stabilizes in about one week.

---

Q: Can Citafort be taken with common over-the-counter pain relievers?

Official warnings caution against combining this medication with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), which include common OTC pain relievers like ibuprofen or naproxen. The concern described in regulatory documents is an increased potential risk for bleeding or bruising when these types of medications are taken together.

---

Q: Are there any foods or supplements that are known to interfere with Citafort?

Official pharmacological data indicates that the medicine's absorption is not affected by food, meaning it can be taken with or without meals. However, regulatory documents warn against combining it with other serotonergic substances, specifically mentioning the herbal supplement St. John's wort.

---

Q: What is the risk of stopping Citafort abruptly?

Regulatory labeling describes that abrupt cessation is discouraged. Official guidelines describe that a gradual dose reduction (tapering) is generally described as minimizing the risk of withdrawal symptoms. These symptoms can include feelings of dizziness, headache, nausea, and electric shock-like sensations.

---

Q: Are there any common misuses of Citafort that people should be aware of?

The primary warnings in official drug documents concern the process of ending treatment. It is documented that following the gradual dose reduction instructions is important, as stopping abruptly can lead to unpleasant physical withdrawal symptoms. Regulatory information also advises close monitoring for any new or worsened psychiatric symptoms, particularly at the start of treatment.

---

Q: Is it normal to feel a change in appetite while taking Citafort?

Yes, changes in appetite are recognized among the commonly reported adverse effects. Official prescribing information lists a decreased appetite as a potential adverse effect of the medicine.

---

Q: Can Citafort affect the results of certain lab tests?

The official product information notes that the medication is associated with a possible decrease in the body's sodium levels, a condition known as hyponatremia. It is also documented that the medicine may alter platelet function, which is a factor that can impact results related to blood clotting.

---

Q: Is it possible to become dependent on Citafort?

Official sources indicate the medication is not addictive or habit-forming like controlled substances, but the body can develop physical dependence after long-term use. The recommended process involves gradual reduction to manage potential physical withdrawal symptoms upon stopping.

---

Q: How long does Citafort stay in the body after the last dose?

The prescribing information contains pharmacokinetic data which shows how long the drug remains active. The medication has a mean terminal half-life of approximately 27 to 32 hours, meaning it takes about that long for half of the drug to be eliminated from the body.

---

Q: Can Citafort cause changes in mood or personality?

Official warnings describe that careful monitoring is recommended for patients, especially young adults, for new or worsening symptoms of depression, anxiety, agitation, and other unusual changes in behavior or mood.

---

Q: Is Citafort known to cause weight changes?

Yes, the prescribing information notes that significant changes in weight may occur. Adverse reaction data documents that both weight loss and weight gain are possible side effects associated with the use of the medicine.

---

Q: Can Citafort affect a person's ability to drive or operate machinery?

The official medication guide includes a warning about operating machinery. Because the drug can cause sleepiness or affect a person's ability to think clearly, official regulatory documents include a warning that driving or operating heavy machinery should be avoided until the effects of the drug are known.

The storage and disposal of Citafort must strictly adhere to regulatory labeling to maintain product stability and ensure safety.

Storage Scope	Requirements (Official Labeling)
Temperature	Store at room temperature, generally below 30 C; do not freeze [Regulatory Documents].
Protection	Keep the product away from heat, moisture, and direct light; container must be tightly closed [Regulatory Documents].
Child Safety	Store the medicine out of the reach and sight of children [Regulatory Documents].
Disposal	Preferred disposal is via a drug take-back program. Otherwise, mix the product with an undesirable substance, seal it, and discard in household trash; do not flush [FDA Guidance].

These official requirements define that the medicine must be protected from environmental degradation and accidental ingestion. The product's stability is maintained by avoiding freezing and excessive moisture. Disposal must follow procedures (take-back or household trash mixing) to prevent unauthorized use and environmental release, as directed by the FDA.